Lung Disease
Conditions
Keywords
COPD, Emphysema
Brief summary
Chronic Obstructive Pulmonary Disease (COPD) is a lung-related disorder that is characterized by long-term, often progressive state of poor airflow. Primary symptoms include low oxygen tension, shortness of breath, productive cough, and broncho-pulmonary inflammation and interference with oxygen-carbon dioxide exchange. Air pollution and tobacco smoking are felt to be the most common cause of these issues. Diagnostic testing is based on poor airflow measured by lung function studies and whose symptoms do not improve much with antiasthma bronchodilators. Study is an interventional study to document the safety and efficacy of use of AD-cSVF in chronic broncho-pulmonary disease groups.
Detailed description
COPD is often treated by limiting exposure to poor air quality, but there is no cure at this time. Attempted therapy include smoking cessation, vaccinations, respiratory rehabilitation, and attempts of use of bronchodilators and steroids. Many resort to supplemental oxygen therapy, lung transplantation, and antibiotic supportive therapy during exacerbations. As of 2013, COPD involve approximately 5% pf the global populations (approximately 330 million). Most commonly it occurs approximately equally between men/women and result in about 3 million deaths per year. Estimates of economic costs are estimated to be more than 2.1 trillion dollars in 2010. This study includes microcannula harvesting of subdermal adipose tissues, incubation, digestion and isolation of AD-cSVF. This stromal cellular pellet (without actual extracellular matrix or stromal elements) is then suspended in 500 cc sterile Normal Saline (NS) and deployed via peripheral intravenous route. Evaluations of safety issues are measured at intervals (both severe and non-severe categories) and by repeated pulmonary function studies.
Interventions
PROCEDURElipoaspiration
Closed syringe harvesting subdermal fat
PROCEDUREADcSVF
Isolation of AD-cSVF
PROCEDURENormal Saline IV
Normal Saline IV containing AD-cSVF
Sponsors
Terry, Glenn C., M.D.
Healeon Medical Inc
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Prior Diagnosis of moderate to severe COPD * GOLD II a, III, IV
Exclusion criteria
* Pregnant or Lactating Females * Life expectancy of \< 3 months due to concomitant illnesses * Exposure to any investigational drug or procedure with 1 month prior to study entry or enrollment in concurrent study which may interfere with interpretation of study results * Illness which, in investigators judgement, may interfere with the patient' ability to comply with protocol, compromise patient safety, ability to provide informed consent to study, or interfere with interpretation of study outcomes * Subjects on chronic immunosuppressive or chemotherapeutic medications * Known drug or alcohol dependence or other factors which may interfere with study conduct or interpretation of result or in the opinion of investigator are not suitable to participate. * Subjects with documented Alpha-1 Antitrypsin Deficiency (Inherited lung and liver disorder) * Unwilling or not competent to understand and execute an informed consent agreement * Patients positive for Hepatitis (Hepatitis A history excepted)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety - Pulmonary Function | 12 months Evaluate Function and Adverse Events | Pulmonary Function to be Addressed as occurrence or frequency of adverse event during study |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| GOLD Classification | 1 year | Global Initiative for Chronic Obstructive Lung Disease (GOLD) is a COPD staging system based on degree of airflow limitations (obstruction) and measured by pulmonary function studies |
| Change from baseline 6 Minute Walk Test | 12 Months | Exercise capacity measured by distance a patient can walk in 6 minute timeframe |
| Change from Baseline Lung X-Ray | 6 months, 12 months | standard flat film x-ray |
| Change from Baseline Respiratory Rate | 1 month, 6 month, 1 year | Measured rate clinically at rest |
| Change from Baseline SGPT Blood Testing | 1 Month | Measure Blood Serum Glutamate Pyruvate Transaminase (SGPT) elevation with liver damage |
| Pulmonary Function Testing | Baseline, 6 Months | Measure Baseline Pulmonary Function (FEV/FEVi Measure) |
| Change from Baseline SGOT Blood Testing | 1 Month | Measure Blood Serum Glutamate Oxaloacetate Transaminase (SGOT) Measure Blood Elevation with liver damage |
Countries
Honduras, United States
Outcome results
None listed